IPO
-
-
-
-
-
-
-
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest
-
-
-
-
-
-
-
HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens
-
-
-
-
-
-
-
HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
-
-
-
-
-
-
-
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
-
-
-
-
-
122,776 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

